Immunocytological analysis of the Tn associated antigen 83D4 in serous effusions from patients with cancer: comparison with Tn soluble glycoprotein
- PMID: 7629290
- PMCID: PMC502619
- DOI: 10.1136/jcp.48.5.433
Immunocytological analysis of the Tn associated antigen 83D4 in serous effusions from patients with cancer: comparison with Tn soluble glycoprotein
Abstract
Aims: To determine whether the monoclonal antibody (MoAb) 83D4, previously shown to be highly specific for carcinoma cells, can be used as an immunocytological marker to discriminate between benign and malignant cells in serous effusions; and to test for a correlation between expression of the antigen reacting with MoAb 83D4 on effusion cells and the amount of soluble 83D4 antigen in effusion fluids.
Methods: Thirty three pleural and 23 peritoneal effusions from 56 cancer patients with metastatic disease were tested for the presence of Tn associated 83D4 antigen by immunocytochemical staining, and for the presence of soluble antigen in supernatants. The patients had undergone various chemotherapy and radiation therapy protocols.
Results: As a result of the various types of treatment, the cytological characteristics of the cells were often modified and the antigenic epitopes may have been altered. Positive staining for 83D4 MoAb was obtained in 36 (97%) of the 37 malignant effusions, eight (73%) of 11 suspect effusions, and three (38%) of the eight apparently benign effusions (free of malignant cells). In these latter cases, cytological reassessment showed a few suspect cells in two cases. 83D4 soluble antigen was detected in 30 of 37 malignant effusions (81%), five of 11 suspected infusions (46%), and five of eight apparently benign effusions (63%).
Conclusions: Immunocytochemical staining with anti-83D4 antibody is useful for differentiating reactive or atypical mesothelial cells from epithelial cells, especially in breast cancer effusions.
Similar articles
-
Detection of a soluble antigen defined by monoclonal antibody 83D4 in serous effusions associated with breast carcinoma.Cancer. 1992 Apr 1;69(7):1745-9. doi: 10.1002/1097-0142(19920401)69:7<1745::aid-cncr2820690716>3.0.co;2-h. Cancer. 1992. PMID: 1551059
-
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.Hum Pathol. 2000 Sep;31(9):1081-7. doi: 10.1053/hupa.2000.9776. Hum Pathol. 2000. PMID: 11014575
-
Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.Cancer. 2008 Feb 25;114(1):49-56. doi: 10.1002/cncr.23254. Cancer. 2008. PMID: 18098206
-
Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature.Anal Cell Pathol. 2001;23(3-4):107-28. doi: 10.1155/2001/418547. Anal Cell Pathol. 2001. PMID: 12082292 Free PMC article. Review.
-
[Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].Arch Anat Cytol Pathol. 1992;40(4):183-9. Arch Anat Cytol Pathol. 1992. PMID: 1294046 Review. French.
Cited by
-
Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.Oncoimmunology. 2016 Apr 22;5(7):e1171434. doi: 10.1080/2162402X.2016.1171434. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622021 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials